MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
India's Third Giant Leap
This Leap Could Potentially Generate Gains
Far Bigger than Anything We Have Seen in Our Lifetimes
- Home
- Stock Quote
- GENERIC PHARMASEC
GENERIC PHARMASEC Share Price (GESC)
Here is the latest stock price and chart of GENERIC PHARMASEC. For more details, see the GENERIC PHARMASEC company fact sheet and quarterly results. Since such stocks interest you, here's a proven approach to making penny stock investments.
| Live BSE Quotes | Mar 28, 2023 (Close) | ||
|---|---|---|---|
| Price (Rs)2.88 | Open (Rs) 3.05 | High (Rs) 3.17 | Low (Rs) 2.85 |
| % Change-4.32 | Volume 265,920 | Value (Rs) 778,829 | 52-Week H/L 6.79 / 2.85 |
| Live NSE Quotes |
|---|
| Not listed |
| Change | |||||
|---|---|---|---|---|---|
| 1 Day -4.32% | |||||
| Valuation | ||||
|---|---|---|---|---|
| EPS (Rs)* 0.00 | P/E Ratio (x) 622.93 | Market Cap (Rs m) 797.36 | P/BV (x) 5.39 | Dividend Yield (%) 0.00 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
GENERIC PHARMASEC Share Price Today:
GENERIC PHARMASEC last traded price was down 4.3% to Rs 2.9 on the BSE. The total volume of shares traded was 0.3 m.
Overall, the benchmark S&P BSE SENSEX was at 57,613.7 (down 0.1%).
The current market capitalisation of GENERIC PHARMASEC stands at Rs 797.36 m. For more information, check out the list of top 100 companies in India in terms of market cap.
As of December 2022, company promoters held 59.96% stake in GENERIC PHARMASEC, with no shares having been pledged. To know more, check out the latest shareholding pattern of GENERIC PHARMASEC.
FAQs on GENERIC PHARMASEC
What is the GENERIC PHARMASEC share price today?
The last traded price of GENERIC PHARMASEC was Rs 2.9 on the BSE, down 4.3% over the previous close.
What is the market cap of GENERIC PHARMASEC?
The current market capitalisation of GENERIC PHARMASEC stands at Rs 797 m.
What is the Earnings per share (EPS) of GENERIC PHARMASEC?
GENERIC PHARMASEC had an EPS of Rs 0.0 in the latest financial year.
Today's Market
Sensex Today Ends Flat | Adani Group Stocks Fall, Adani Enterprises & Adani Ports Down 7% | JSW Infra Delays Rs 40-bn IPO(Closing)
After opening the day on a positive note, Indian share reversed gains as the session progressed and ended marginally lower.
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks
TRENDING TOPICS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.